

drug in dispersion that is higher than the additive solubility calculated from the drug solubility in the oil and water phases of the dispersion, and the dispersions are organic solvent-free.

*P2
Cmt*
150. Dispersions according to claim 149, wherein the concentration of surfactant, stabilizer or mixtures of surfactants and stabilizers is between 0.1% and 20% by weight.

EXPLANATION OF AMENDMENTS:

The claims have been amended as shown by [deletions] and insertions.

24. (Amended) Dispersion according to claim 1, wherein the dispersion comprises at least one emulsifier selected from the group consisting of egg lecithin, soya lecithin, phospholipids of egg or soya, sorbitan esters, [Span 85] sorbitane trioleate, polyethylene glycol sorbitan esters, [Tween 80] polyoxyethylene sorbitane monooleate, sodium glycocholate, sodium lauryl sulphate, and mixtures thereof.

REMARKS

Reconsideration and allowance of the subject application are respectfully requested.

Claims 1-150 are pending in the application. Claims 16-18, 67-142, 145 and 147 stand withdrawn pursuant to a restriction requirement.

Basis for new claims 149 and 150 can be found in the present specification and original claims. No new matter has been added. No claims have been amended to overcome prior art.

New claims 149 and 150 relate to the elected invention of Group I.

The rejection of claims 1 and 24 under 35 U.S.C. § 112, second paragraph, is respectfully traversed. Applicant submits that claim 1 fully complies with Section 112. Applicant has amended claim 24 to remove reference to the trademarks and replace them with the commonly known chemical nomenclature. No new matter has